// STATE LEGISLATION TRACKER

Vermont H266: An act relating to the 340B prescription drug pricing program

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Vermont
Bill: H266
Session: 2025-2026
Filed: 2025-02-19
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Vermont H266 protects 340B covered entities and contract pharmacies from discrimination or interference by manufacturers, PBMs, insurers, and other payors. It does not appear to target compounded peptides, off-label prescribing, telehealth, NP or naturopath scope, controlled substances, prescription monitoring, or FDA 503A/503B compounding.

Key Points

No direct change to peptide prescribing or access rules
No visible impact on telehealth peptide visits
No change to NP or naturopath prescribing scope
No peptide-specific compounding language identified
May matter only if a 340B clinic dispenses a covered drug

What to Watch For

Note Clinics using 340B may see stronger protection against manufacturer or PBM interference.

Note Peptide users should not treat this as changing compounded peptide legality or FDA compounding rules.

Note Any indirect effect would be limited to drugs handled through 340B covered entities or contract pharmacies.

Where the Bill Stands

The Governor approved the bill on June 11, 2025, so it has been signed into law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws